UK markets close in 3 hours 33 minutes

Carisma Therapeutics, Inc. (W2J.F)

Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
1.4690-0.0500 (-3.29%)
As of 09:59AM CEST. Market open.
Currency in EUR

Valuation measures4

Market cap (intra-day) 62.02M
Enterprise value -7.48M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)3.66
Price/book (mrq)2.55
Enterprise value/revenue -0.50
Enterprise value/EBITDA 0.09

Trading information

Stock price history

Beta (5Y monthly) N/A
52-week change 3-66.69%
S&P500 52-week change 322.43%
52-week high 38.6000
52-week low 31.4690
50-day moving average 32.0055
200-day moving average 33.0115

Share statistics

Avg vol (3-month) 3219
Avg vol (10-day) 311
Shares outstanding 541.54M
Implied shares outstanding 642.08M
Float 822.51M
% held by insiders 128.68%
% held by institutions 140.81%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Currency in USD.

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)-602.71%

Management effectiveness

Return on assets (ttm)-68.59%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)14.92M
Revenue per share (ttm)0.44
Quarterly revenue growth (yoy)15.00%
Gross profit (ttm)N/A
EBITDA -85.89M
Net income avi to common (ttm)-86.88M
Diluted EPS (ttm)-2.4200
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)77.61M
Total cash per share (mrq)1.87
Total debt (mrq)3.12M
Total debt/equity (mrq)11.77%
Current ratio (mrq)5.06
Book value per share (mrq)0.65

Cash flow statement

Operating cash flow (ttm)-81.18M
Levered free cash flow (ttm)-51.52M